Cargando…
2352. Clinician Assessment of Pretest Probability for Clostridioides difficile Infection and Disease Severity While Using Multiplex, Syndromic Molecular Panel in Patients Presenting with Diarrhea
BACKGROUND: The role of nucleic acid amplification tests (NAAT) for diagnosing Clostridioides difficile (CD) infection remains controversial. Adding CD to multiplex molecular panels (GIPCR) that detects multiple GI pathogens of community origin, has the potential to introduce confusion leading to de...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810244/ http://dx.doi.org/10.1093/ofid/ofz360.2030 |
_version_ | 1783462202974404608 |
---|---|
author | Throneberry, S Kyle Lopansri, Bert K Grisel, Nancy A |
author_facet | Throneberry, S Kyle Lopansri, Bert K Grisel, Nancy A |
author_sort | Throneberry, S Kyle |
collection | PubMed |
description | BACKGROUND: The role of nucleic acid amplification tests (NAAT) for diagnosing Clostridioides difficile (CD) infection remains controversial. Adding CD to multiplex molecular panels (GIPCR) that detects multiple GI pathogens of community origin, has the potential to introduce confusion leading to delayed diagnosis and unnecessary antibiotic use especially if pretest probability is not considered. METHODS: We conducted a retrospective study to determine the frequency at which clinicians characterize pretest probability and disease severity in adult patients with diarrhea who tested positive for CD by GIPCR (BioFire, Inc.) from July 1, 2017 to October 16, 2018. We excluded immunocompromised patients. Routine testing includes reflex to GDH and toxin A/B detection when GIPCR is positive for CD. Charts were reviewed and clinical suspicion (PTP) was assigned as high, medium, low, or not done. Disease severity was classified as mild, moderate and severe. Exposure to systemic antibiotic within 90 days prior to testing and stool frequency was also captured. RESULTS: In total, 447 patients were included in the analysis: 110 (24.6%) were positive for both GDH and Toxin (G+/T+), 158 (35.3%) were G+/T−, 179 (40%) were G−/T−, and 149 (33%) were not classified. Toxin positivity was highest in the setting of high PTP (67%) (figure). In contrast, toxin was negative in most cases when suspicion for CDI was low or not characterized (81%). For medium suspicion, only 36% were T+. Antibiotic exposure prior to testing was observed in 203 (45%) of the cases. More G+/T+ patients received antibiotics (63%) before testing and 66% of G−/T− did not receive antecedent antibiotics. Clinicians did not characterize frequency of diarrhea in 261 (58%) of the patients tested and 95% of cases did not undergo severity classification. When documented, 24% of tested patients had < 3 diarrheal episodes/day (Table 1). Most cases where multiple pathogens were detected were T− (84.5%) and G−/T− (44%) (Table 2). CONCLUSION: Overall, characterization of diarrheal illness was poor and PTP was frequently omitted. A large proportion of GIPCR results positive for CD (40%) were negative for both GDH and Toxin. CD results in molecular testing with syndromic panels should be interpreted with caution. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6810244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68102442019-10-28 2352. Clinician Assessment of Pretest Probability for Clostridioides difficile Infection and Disease Severity While Using Multiplex, Syndromic Molecular Panel in Patients Presenting with Diarrhea Throneberry, S Kyle Lopansri, Bert K Grisel, Nancy A Open Forum Infect Dis Abstracts BACKGROUND: The role of nucleic acid amplification tests (NAAT) for diagnosing Clostridioides difficile (CD) infection remains controversial. Adding CD to multiplex molecular panels (GIPCR) that detects multiple GI pathogens of community origin, has the potential to introduce confusion leading to delayed diagnosis and unnecessary antibiotic use especially if pretest probability is not considered. METHODS: We conducted a retrospective study to determine the frequency at which clinicians characterize pretest probability and disease severity in adult patients with diarrhea who tested positive for CD by GIPCR (BioFire, Inc.) from July 1, 2017 to October 16, 2018. We excluded immunocompromised patients. Routine testing includes reflex to GDH and toxin A/B detection when GIPCR is positive for CD. Charts were reviewed and clinical suspicion (PTP) was assigned as high, medium, low, or not done. Disease severity was classified as mild, moderate and severe. Exposure to systemic antibiotic within 90 days prior to testing and stool frequency was also captured. RESULTS: In total, 447 patients were included in the analysis: 110 (24.6%) were positive for both GDH and Toxin (G+/T+), 158 (35.3%) were G+/T−, 179 (40%) were G−/T−, and 149 (33%) were not classified. Toxin positivity was highest in the setting of high PTP (67%) (figure). In contrast, toxin was negative in most cases when suspicion for CDI was low or not characterized (81%). For medium suspicion, only 36% were T+. Antibiotic exposure prior to testing was observed in 203 (45%) of the cases. More G+/T+ patients received antibiotics (63%) before testing and 66% of G−/T− did not receive antecedent antibiotics. Clinicians did not characterize frequency of diarrhea in 261 (58%) of the patients tested and 95% of cases did not undergo severity classification. When documented, 24% of tested patients had < 3 diarrheal episodes/day (Table 1). Most cases where multiple pathogens were detected were T− (84.5%) and G−/T− (44%) (Table 2). CONCLUSION: Overall, characterization of diarrheal illness was poor and PTP was frequently omitted. A large proportion of GIPCR results positive for CD (40%) were negative for both GDH and Toxin. CD results in molecular testing with syndromic panels should be interpreted with caution. [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810244/ http://dx.doi.org/10.1093/ofid/ofz360.2030 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Throneberry, S Kyle Lopansri, Bert K Grisel, Nancy A 2352. Clinician Assessment of Pretest Probability for Clostridioides difficile Infection and Disease Severity While Using Multiplex, Syndromic Molecular Panel in Patients Presenting with Diarrhea |
title | 2352. Clinician Assessment of Pretest Probability for Clostridioides difficile Infection and Disease Severity While Using Multiplex, Syndromic Molecular Panel in Patients Presenting with Diarrhea |
title_full | 2352. Clinician Assessment of Pretest Probability for Clostridioides difficile Infection and Disease Severity While Using Multiplex, Syndromic Molecular Panel in Patients Presenting with Diarrhea |
title_fullStr | 2352. Clinician Assessment of Pretest Probability for Clostridioides difficile Infection and Disease Severity While Using Multiplex, Syndromic Molecular Panel in Patients Presenting with Diarrhea |
title_full_unstemmed | 2352. Clinician Assessment of Pretest Probability for Clostridioides difficile Infection and Disease Severity While Using Multiplex, Syndromic Molecular Panel in Patients Presenting with Diarrhea |
title_short | 2352. Clinician Assessment of Pretest Probability for Clostridioides difficile Infection and Disease Severity While Using Multiplex, Syndromic Molecular Panel in Patients Presenting with Diarrhea |
title_sort | 2352. clinician assessment of pretest probability for clostridioides difficile infection and disease severity while using multiplex, syndromic molecular panel in patients presenting with diarrhea |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810244/ http://dx.doi.org/10.1093/ofid/ofz360.2030 |
work_keys_str_mv | AT throneberryskyle 2352clinicianassessmentofpretestprobabilityforclostridioidesdifficileinfectionanddiseaseseveritywhileusingmultiplexsyndromicmolecularpanelinpatientspresentingwithdiarrhea AT lopansribertk 2352clinicianassessmentofpretestprobabilityforclostridioidesdifficileinfectionanddiseaseseveritywhileusingmultiplexsyndromicmolecularpanelinpatientspresentingwithdiarrhea AT griselnancya 2352clinicianassessmentofpretestprobabilityforclostridioidesdifficileinfectionanddiseaseseveritywhileusingmultiplexsyndromicmolecularpanelinpatientspresentingwithdiarrhea |